No leniency for Shkreli: Bad-boy pharma executive gets 7 years in prison for fraud

Martin Shkreli's lawyers had sought a sentence of between 12 and 18 months. (Image: House Committee on Oversight and Government Reform)

The sentence is in. Despite pleas for sentencing mercy, “Pharma Bro” Martin Shkreli will spend up to seven years in prison on federal securities fraud charges.

U.S. District Judge Kiyo Matsumoto, who also fined Shkreli $75,000, handed down the decision Friday afternoon after a hearing that began with a request for leniency from Shkreli’s lawyer, reports say.

“I’ve got my begging voice on,” Shkreli lawyer Benjamin Brafman told the judge, as quoted by Reuters.

On-Demand Webinar

De-Risking the Solid Form Landscape of an API

This presentation will discuss how predictable stability and solubility can minimize development timelines and cost. Attend to hear about two case studies exemplifying the importance of understanding the hydration space of an API and how hydrate formation may be avoided by development of a robust crystallization procedure.

RELATED: Judge's ruling sets Shkreli up for possible 10 years in prison, but he seeks leniency for his good deeds

Shkreli, notorious for a demeanor that’s been labeled “cocky,” “insolent” and “remorseless,” cried as he addressed the judge, saying that “the only person to blame for me being here today is me.”

"I took down Martin Shkreli,” he said.

While the seven-year sentence is far above the 12 to 18 months Shkreli’s lawyers sought, it’s also well below the 15-plus years prosecutors have been eyeing. And the time he’s already spent in jail—about six months—will count toward the sentence.

RELATED: Pharma bro Martin Shkreli convicted of securities fraud

A New York jury convicted Shkreli back in August of three of eight charges, including securities fraud. He was released on a $5 million bond that the judge later revoked after Shkreli served up a social media post offering $5,000 to whomever could bring him a lock of Hillary Clinton’s hair.

It was Shkreli’s 5,000% price hike on HIV-related drug Daraprim, though, that in September 2015 earned him the title of “most hated man in America” and made headlines around the globe.

Suggested Articles

Johnson & Johnson and Bayer’s Xarelto is working to reverse a sales slide, and a new indication could help.

AZ's FluMist will be dramatically limited in the U.S. this flu season because of production problems, a spokeswoman said.

To get its $12 billion opioid deal off the ground, Purdue Pharma pushed for a stay on thousands of lawsuits against it. Last week, a judge signed off.